Frontlight ResearchEarly access
Not yet recruitingPhase 3
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
Key facts
- Who runs it
- Institut Gustave Roussy
- Where
- France16 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 984 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 1 Sept 2030
- Type of study
- Interventional
- Record updated
- 28 January 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Women, men, transgender,18 ≤age ≤55
- ECOG performance status ≤ 1
- Patients infected with HIV are eligible for the study provided they are receiving antiretroviral therapy with undetectable viral load
- Biopsy-proven HPV related HSIL at any site (vulvar VIN, vaginal VaIN, cervical CIN, anal AIN, penile) at baseline
- Women of childbearing potential must have a negative urine pregnancy test 24 hours prior to the administration of the first vaccine injection
- Sexually active patients must agree to use acceptable and appropriate contraception while included in BIO-HPV study and until the last dose of vaccine
- Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol
- Patients must be affiliated to a social security system or beneficiary of the same
- Life expectancy of greater than 5 years
Who cannot take part
- History of prior treatment of HSIL at the same site then currently treated
- Prior HPV vaccination
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 21 days prior to the first dose of trial treatment
- Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment
- History of HPV related cancer (i.e. anal, genital, head and neck)
- Prior malignancy active within the previous 3 years except from cancers with an expected PFS at 5 years of >95%
- Hypersensitivity to the active substances or to any of the excipients (Listed in the SmPC)
- Acute or severe febrile illness. Vaccination must be postponed until the individual has fully recovered
- Pregnant women or intent to become pregnant
- Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
- Warts so extensive that they preclude the clinician from determining the extent and location of HSIL
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the efficacy of Human papilloma virus (HPV) vaccination as secondary prevention in patients with gynecological or anal HSIL.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from 2024-520140-42-00, who can take part
- Record updated
- 28 January 2026